NL-OMON30106已完成不适用
The effect of Trastuzumab treatment on B-cell kinase activities assessed by microarray derived phosphorylation profiles. - Trastuzumab and HER kinase profiling.
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients who will be treated with trastuzumab in their best interest as single agent or in combination with chemo- or hormonal therapy (15 patients), or who are about to discontinue treatment with trastuzumab (15 patients for elimination curve), Age >18 years, written informed consent prior to participation in the trial, Able and willing to undergo blood and urine sampling.
排除标准
- •The common exclusion criteria regarding trastuzumab treatment will be followed, and left to the discretion of the treating physician.
研究者
相似试验
已完成
1 期
Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast CancerRecurrent Breast CancerNCT02843126Fuda Cancer Hospital, Guangzhou30
撤回
不适用
Ramucirumab, Paclitaxel, and Trastuzumab biosimilar combination treatment in HER2 positive metastatic gastric cancer patientsNeoplasmsKCT0003638Chonbuk National University Hospital53
尚未招募
不适用
Phase II Study of Abemaciclib plus Trastuzumab biosimilar(Herzuma®) ± Fulvestrant in Patients with HER2 Positive Metastatic Breast Cancer in Brain who Progressed after HER2 directed ChemotherapyKCT0004338Korea University Anam Hospital48
已完成
1 期
Combination of Rituximab and NK Immunotherapy for B LymphomaB-cell Lymphoma RecurrentNCT02843061Fuda Cancer Hospital, Guangzhou30
已完成
不适用
The effect of TNFa-blockers on B-cells in patients with granulomatous diseases.Inflammatory systemic diseases1001796910003816NL-OMON41509Erasmus MC, Universitair Medisch Centrum Rotterdam40